Shares of NovoCure Limited (NASDAQ:NVCR – Get Free Report) have received an average rating of “Moderate Buy” from the six ratings firms that are presently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $26.17.
Several brokerages have recently issued reports on NVCR. Wells Fargo & Company decreased their target price on NovoCure from $42.00 to $40.00 and set an “overweight” rating for the company in a research report on Friday, July 26th. Wedbush restated an “outperform” rating and set a $24.00 price objective on shares of NovoCure in a report on Thursday, July 25th. HC Wainwright upgraded shares of NovoCure from a “neutral” rating to a “buy” rating and boosted their target price for the company from $24.00 to $30.00 in a research note on Wednesday, October 16th. Finally, Evercore ISI decreased their price target on shares of NovoCure from $21.00 to $18.00 and set an “in-line” rating for the company in a research note on Tuesday, October 1st.
Check Out Our Latest Analysis on NVCR
Institutional Investors Weigh In On NovoCure
NovoCure Stock Up 1.2 %
Shares of NVCR stock opened at $16.37 on Tuesday. The company has a quick ratio of 6.22, a current ratio of 6.46 and a debt-to-equity ratio of 1.81. NovoCure has a 52-week low of $10.87 and a 52-week high of $24.74. The company has a 50-day simple moving average of $16.95 and a two-hundred day simple moving average of $17.79.
NovoCure (NASDAQ:NVCR – Get Free Report) last released its earnings results on Thursday, July 25th. The medical equipment provider reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.09. The company had revenue of $150.40 million during the quarter, compared to analyst estimates of $135.83 million. NovoCure had a negative return on equity of 45.68% and a negative net margin of 30.67%. NovoCure’s quarterly revenue was up 19.3% on a year-over-year basis. During the same period in the prior year, the company posted ($0.54) earnings per share. As a group, sell-side analysts forecast that NovoCure will post -1.35 earnings per share for the current fiscal year.
NovoCure Company Profile
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua.
Read More
- Five stocks we like better than NovoCure
- Investing in Travel Stocks Benefits
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- What Are Trending Stocks? Trending Stocks Explained
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- Find and Profitably Trade Stocks at 52-Week Lows
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for NovoCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure and related companies with MarketBeat.com's FREE daily email newsletter.